ライフサイエンスコーパス: stakeholder

1 orded the status of 'Data Safe Haven' by key stakeholders'?

2 tructured, and do not involve all of the key stakeholders.

3 s well as coordinated efforts among critical stakeholders.

4 rovide additional tools to fishers and other stakeholders.

5 anizations, and input from experts and other stakeholders.

6 ng with coaching calls and engagement of key stakeholders.

7 ists' ideals and practices when working with stakeholders.

8 review and 33 semistructured interviews with stakeholders.

9 torship program and involvement of the 4 key stakeholders.

10 trategies between environmental and industry stakeholders.

11 as a performance function of time set by the stakeholders.

12 litative interviews with a range of involved stakeholders.

13 cess included representation from a range of stakeholders.

14 in close consultation with central and field stakeholders.

15 one of multiple partnerships with different stakeholders.

16 surgeons, PRO researchers, payers, and other stakeholders.

17 subsequently defined in agreement with local stakeholders.

18 ng process being communicated clearly to all stakeholders.

19 the STS and the ACC in concert with multiple stakeholders.

20 values, expectations and concerns of diverse stakeholders.

21 ve roles of professional societies and other stakeholders.

22 e conservationists, invasion biologists, and stakeholders.

23 alternative future scenarios for a range of stakeholders.

24 ted and are viewed as trustworthy by diverse stakeholders.

25 s differentially affecting various groups of stakeholders.

26 ystematic, coordinated efforts among various stakeholders.

27 o an example and considered implications for stakeholders.

28 rivate partnerships and involvement from all stakeholders.

29 statisticians, healthcare planners and other stakeholders.

30 th staff, patients, relatives, volunteers or stakeholders.

31 guidelines through the participation of key stakeholders.

32 and requests for NTP's products by external stakeholders.

33 l, which might be nontransparent to affected stakeholders.

34 st the trend; and engagement with a range of stakeholders.

35 l rule, and commentary submitted by relevant stakeholders.

36 gress, and potential synergies with relevant stakeholders.

37 sense of empowerment and agency amongst all stakeholders.

38 partly conflicting ideals when working with stakeholders.

39 involvement (6 reviews/overviews); involving stakeholders (5 reviews/overviews); leadership support (

40 These findings offer clinicians and stakeholders a comprehensive assessment and high-quality

41 and Relevance: Through direct engagement of stakeholders, a QPL was created to address core decision

42 al conference) with geographically dispersed stakeholders, a totally new concept for them.

43 in aquaculture must include education of all stakeholders about its detrimental effects on the health

44 y coverage, (iv) scientific quality, and (v) stakeholder acceptance.

45 are arrangements regarding participation of stakeholders, accountability in governance, and the use

46 of a diverse collection of disaster research stakeholders across a broad spectrum of disciplines.

47 clinicians and the other to a wider group of stakeholders across Europe.

48 This meeting report is a call to those stakeholders across the globe to actively participate in

49 Stakeholders actively discuss ways to measure safety and

50 ditions, or aspects of health) that relevant stakeholders agree are essential to assess in all clinic

51 All contributing stakeholders agree that PAL must reflect actual risk.

52 for Breast Health is a successful example of stakeholder and collaborator involvement-both internal a

53 ishment of a panel representing all relevant stakeholders and a research team experienced in outcomes

54 decision-making framework that incorporates stakeholders and accounts for real-world resource, suppl

55 nd collaborative processes to engage diverse stakeholders and address inequalities.

56 lysis of large amounts of data with multiple stakeholders and collaborators across various user-acces

57 ne development effort that included clinical stakeholders and conformed to the Institute of Medicine'

58 tidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine'

59 nt a protocol to decrease POAF: (1) identify stakeholders and form a working committee, (2) formal li

60 sues and to include in its assessments local stakeholders and indigenous and traditional systems of k

61 Key barriers included a wide range of stakeholders and lack of ownership and accountability of

62 To update program stakeholders and other healthcare systems facing such ch

63 ystems provide to people, our models allowed stakeholders and policymakers to refine zones of human u

64 ject, a communications strategy that engaged stakeholders and potential supporters was developed.

65 DG, PH, and SP) did a survey of professional stakeholders and then used a scenario planning technique

66 ions in hindcasts, a relationship with local stakeholders, and a real-time observational network.

67 ng collaboration with experts and a range of stakeholders, and be dependent on the emergence of new e

68 over resource location and function, diverse stakeholders, and fragmented regulatory authority.

69 es; 3) develop networks of collaborators and stakeholders, and launch transformative studies that can

70 tions focus on 3 key domains: the scope, the stakeholders, and the consensus process.

71 y funded studies that have fully engaged key stakeholders are described.

72 unications between neuroscientists and other stakeholders are different from those that characterize

73 Concerted efforts by all stakeholders are highly needed.

74 Healthcare stakeholders are unclear about the clinical utility of N

75 od provides additional useful information to stakeholders as well as it reduces the computational tim

76 timates that decompose the cost by different stakeholders (as proposed in our framework), that consid

77 ions, and strengthening partnership with key stakeholders at the operational level, including communi

78 ted States, including the roles of all 4 key stakeholders, because to our knowledge, this has never b

79 Our key messages are directed at many global stakeholders, but the central message is that to deliver

80 gulators, public health officials, and other stakeholders can better ameliorate impacts and prevent f

81 h the template matching audit, hospitals and stakeholders can better understand where this excess var

82 Nevertheless, all stakeholders can contribute to improvements in food safe

83 ne against which local, national, and global stakeholders can map the pathways for ending preventable

84 Local stakeholders charged with developing flexible and tailor

85 tion may improve critical care delivery, yet stakeholders cite concerns about its feasibility.

86 macopeial Convention (USP) and international stakeholders collaborated to redefine quality expectatio

87 Multiorganisational stakeholder collaboration is needed for the development

88 ch researchers can help build capacities for stakeholder collaboration, social learning, knowledge go

89 structure capacity, and systems facilitating stakeholder collaboration.

90 n Tool (DPT), was developed to help national stakeholders combine existing data and local expertise t

91 s the needs as perceived by the tuberculosis stakeholder community and attempts to provide a means of

92 This article describes the efforts by the stakeholder community that led to the identification of

93 ed on information gathered from the lagoons' stakeholders, complemented by scientific knowledge on ea

94 utcomes in Nephrology-Kidney Transplantation stakeholder consensus workshops in Boston (17 patients/c

95 st to establish a comprehensive and multiple-stakeholder consented topic list designed for guiding th

96 s showed that providers, patients, and other stakeholders consider HIE to be valuable, but barriers i

97 Following analytical work and stakeholder consultations, the IPV Immunization Systems

98 the basis of multicountry analyses and multi-stakeholder consultations, we propose national targets f

99 Stakeholders continue to discuss the role of using inact

100 Key stakeholder contributions included selection of patient-

101 Priority should be placed on enhancing stakeholder cooperation at the major basin scale towards

102 to provide a platform through which country stakeholders, development partners, and technical expert

103 stitutes a significant challenge for the key stakeholders due to the combined effects of chronic illn

104 igators and proposes collaboration among all stakeholders earlier in the development process.

105 ction and communication between multiple key stakeholders (ecological framework), the central and oft

106 may be informative to policymakers and other stakeholders engaged in restructuring graduate medical t

107 Based on given goals, stakeholders engaged in this study selected the followin

108 arch, we must foster collaboration among all stakeholders engaged in tuberculosis research and contro

109 This included efforts to facilitate stakeholder engagement and ownership, strengthen coordin

110 Stakeholder engagement has the potential to develop rese

111 sts of capacity building to allow meaningful stakeholder engagement in water-management decision proc

112 Stakeholder engagement incorporated the perspectives of

113 This article describes the effect of stakeholder engagement on the design of a randomized tri

114 The study team developed and implemented a stakeholder engagement process that provided iterative f

115 Stakeholder engagement was a useful framework for develo

116 torical practices, complex multidisciplinary stakeholder engagement, and adoption of length of stay a

117 ough a year-long process of multidimensional stakeholder engagement, the research team successfully r

118 Through iteration of modeling and stakeholder engagement, we developed a preferred plan, c

119 standard survey goals including large-sample stakeholder engagement.

120 s related to study development, funding, and stakeholder engagement.

121 The PFAC members and other stakeholders evaluated 118 publicly available questions

122 Stakeholders explored and deliberated over trade-offs su

123 Stakeholder feedback and inclusive strategy should be co

124 re scored anonymously by 162 researchers and stakeholders from 39 countries according to five criteri

125 ance (the Alliance) convened a think tank of stakeholders from academia, government, industry, and pa

126 ronment for cardiovascular drug development, stakeholders from academia, industry, regulatory bodies,

127 embryo editing developments, scientists and stakeholders from all nations should cooperate to take a

128 ted the need to improve the participation of stakeholders from developing countries in the IPM adopti

129 recommendations were addressed to five main stakeholders-funders, regulators, journals, academic ins

130 ough structured conversations via a range of stakeholders (general dental practitioners, patients, in

131 Stakeholders generally supported increasing harmonizatio

132 r longer-term funding; towards defined multi-stakeholder governance and away from traditional governm

133 ast 70% of the voting participants from each stakeholder group providing a score between 7 and 9.

134 on-makers, industry professionals, and other stakeholder groups due to the lack of quantitative risk,

135 ed surveys of participants representing four stakeholder groups relevant to clinical research evaluat

136 dvocacy organizations, industry/professional stakeholder groups, and clinical/basic science academici

137 ing nearly 200 participants representing key stakeholder groups, followed by a consensus meeting.

138 momentum will probably move strongly across stakeholder groups, if collaborative relationships evolv

139 study management group representing multiple stakeholder groups.

140 ing nearly 250 participants representing key stakeholder groups.

141 re engagement across many research areas and stakeholder groups.

142 rbidities were critically important for both stakeholder groups.

143 ownstream implications for patient and payer stakeholder groups.

144 common problem with a negative impact on all stakeholders (> 80%) and perceived that improved advance

145 econd round response rates were high for all stakeholders (>80%).

146 anizations, academic institutions, and other stakeholders has assembled to address the unmet need for

147 pen and constructive dialogue among European stakeholders has positively affected development of trea

148 Nephrology stakeholders have an urgent obligation to initiate well

149 Over time, other stakeholders have placed additional requirements on the

150 Over the past several years, multiple stakeholders have worked to develop consensus regarding

151 l framework (the health issue, intervention, stakeholders, health system, and context) to assess faci

152 ations will require a timely response by all stakeholders identified in the report and a coordinated

153 ng patients about asthma diagnosis, engaging stakeholders in all aspects of study design and implemen

154 ies, and highlight the need to include local stakeholders in conservation planning of Amazonian flood

155 potentially useful for poultry producers and stakeholders in designing risk-based surveillance, outre

156 cilitated through greater involvement of all stakeholders in discussions and decision-making in order

157 A cooperative effort of stakeholders in Duchenne muscular dystrophy-including re

158 ined in-depth interviews with a range of key stakeholders in health and mental health, analysis of me

159 n Surgery (PROS) Conference brought together stakeholders in PROs research in surgery with the aim of

160 illingness to donate eyes are high among the stakeholders in Srikakulam district in India.

161 researchers, funders, regulators, and other stakeholders in stroke research might consider these rec

162 importantly engagement of patients and other stakeholders in study design and troubleshooting, and fl

163 The updated ranking allows stakeholders in the agriculture sector and regulatory ag

164 n depends on the awareness levels of various stakeholders in the community.

165 k) established recently by the FDA and major stakeholders in the Drug Discovery field for the validat

166 h aims to further the conversation among all stakeholders in the interactions between science, techno

167 ic brain tumors has heralded an era in which stakeholders in the pediatric neuro-oncology community a

168 dren's Fund (UNICEF), and other partners and stakeholders in the region and globally were significant

169 In the last few years, stakeholders in the scientific community have raised ala

170 sed decision support in LCA is a way to help stakeholders in their decision-making process.

171 the role of regulatory authorities and other stakeholders in this challenging situation, and the pote

172 e addressed and consensually accepted by the stakeholders in this field.

173 ide an ethical framework to guide transplant stakeholders in using social media for public and patien

174 lved partnerships with the media and various stakeholders including African ministries of health, the

175 broad and informed discussion involving all stakeholders including researchers, clinicians, patients

176 nstrated by showing the effect on a range of stakeholders including service users, patients, carers,

177 to summarize the perspectives of all the key stakeholders (including clinicians, patients, food indus

178 Multiple stakeholders, including academia, federal funding agenci

179 Americans require input from a broad set of stakeholders, including clinicians and researchers from

180 stem cell research aimed at a wide range of stakeholders, including research consortia, biorepositor

181 earch; and (4) recommendations for different stakeholders, including researchers, regulatory authorit

182 y targets was ongoing communication with key stakeholders, including switch-country national regulato

183 Efforts are needed by all stakeholders, including WHO, WHO Member States, and civi

184 For this to succeed, different stakeholders-including national governments, global dono

185 f sound dialogue and learning among publics, stakeholders, industry, and regulatory decision makers.

186 pancies in the prioritization of death among stakeholders-inevitability of death (patients), preventi

187 nt public process to solicit and incorporate stakeholder input.

188 s, such as improving workforce diversity and stakeholder interactions, on which the community has yet

189 Using geospatial analyses and stakeholder interviews, we quantify the impact of CAR on

190 bservation instruments, document review, and stakeholder interviews.

191 h data presents immense opportunities to all stakeholders involved in cardiology research and practic

192 conducted 74 semi-structured interviews with stakeholders involved in health agenda setting and surgi

193 cy makers, civil society, funders, and other stakeholders involved with health agenda setting and sur

194 This paper evaluates current stakeholder involvement (SI) practices in science throug

195 science should include early and continuous stakeholder involvement and the use of conceptual framew

196 recommend this GL for use." The domains of "Stakeholder involvement" and "Rigor of Development" only

197 ices and balancing the well-being of diverse stakeholders involves different kinds of trade-offs.

198 l development and engagement with additional stakeholders is required.

199 lth response that spans multiple sectors and stakeholders is urgently needed.

200 is curated and made widely available to all stakeholders, it is hoped that it will enhance therapeut

201 Different configurations of stakeholders (knowledge brokers, assessment teams, imple

202 ternational collaboration among all relevant stakeholders leading to harmonised case definitions and

203 f practices at levels considered feasible to stakeholders led to nearly reaching TP targets for weste

204 rage costs at well-sited locations, but some stakeholders may incur substantial costs.

205 This report summarizes findings from the stakeholders meeting and seeks to establish a platform f

206 ican College of Cardiology (ACC) sponsored a stakeholders meeting on October 1 to 2, 2015, in Washing

207 disciplinary scientific experts and affected stakeholders (more than 1000 in total): individuals with

208 nment of health care provider organizations, stakeholders must understand the implications of misalig

209 SN-affiliated countries with sampling of key stakeholders (national nephrology society leadership, po

210 For adaptation and mitigation planning, stakeholders need reliable information about regional pr

211 Stakeholders need to come together to determine the best

212 ore, to combat the threat of resistance, key stakeholders need to rapidly embrace a multifaceted appr

213 Governments, together with a broad range of stakeholders, need to act urgently to decrease the preva

214 Stakeholders of an effective mentorship program should i

215 educators, clinicians, researchers, and key stakeholders on how to build further capacity within the

216 ychographic segmentation approach to segment stakeholders on potential barriers to a target behavior.

217 Institute as informed by a diverse group of stakeholders on the management of ductal carcinoma in si

218 We assembled key experts and stakeholders (oncologists, cancer registrars, epidemiolo

219 the kinds of topics scientists work on with stakeholders, over scientific trade-offs that arise in t

220 A larger stakeholder panel then ranked research questions by perc

221 ederal funding agencies increasingly support stakeholder participation in environmental health studie

222 nd systems approaches, new data sources, and stakeholder partnerships.

223 s informed a questionnaire survey that asked stakeholders (patients and professionals) from United Ki

224 ission, we summarise expert opinion from key stakeholders-patients, caregivers, and medical professio

225 favorable alternative from the Environmental stakeholder perspective.

226 senting Environmental, Military and Balanced stakeholder perspectives.

227 ing, compared with earlier versions based on stakeholder preferences alone.

228 he need for a core outcome set that reflects stakeholder priorities.

229 lopment could help discern discordance among stakeholder priorities; facilitate cooperation to align

230 Stakeholders prioritized evidence gaps related to incorp

231 In the implementation domain, stakeholders prioritized understanding strategies to ide

232 These stakeholder-prioritized outcomes will inform the core ou

233 awareness of NTP's work on CrVI by external stakeholders (proximal outcome) and citations of NTP's r

234 Stakeholders ranked evidence gaps by importance from the

235 costs from the perspectives of a variety of stakeholders (relativity), discusses core concepts in ho

236 ed firearms by engaging the public and major stakeholders require urgent implementation and outcome e

237 n terms of reducing delays and costs for all stakeholders (researchers, consumers, regulators, and in

238 Who are the stakeholders responsible for that determination?

239 4 lead scientific reviewers and patient and stakeholder reviewers.

240 ractices, is needed to better understand the stakeholder-scientist nexus.

241 en the research capacity and coordination of stakeholders, scientists, and extension personnel.

242 tinues to proliferate as consumers and other stakeholders seek information on the quality and outcome

243 icy recommendations from the ACP to external stakeholders (such as payers, governmental oversight org

244 chemical testing programs and for achieving stakeholder support of their use.

245 Stakeholders support the inclusion of graft health, mort

246 are commonly participatory, engage multiple stakeholders, support critical discussion about gender r

247 and for providing recommendations that help stakeholders take future decisions.

248 his risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommen

249 al governance, which typically exclude those stakeholders that are most directly linked to the specif

250 continuous channel of communication with all stakeholders that enabled the application of internation

251 e creation of a national consensus among all stakeholders that will allow the advances in therapeutic

252 as created using a modified Delphi survey of stakeholders that will help researchers, surgeons, and f

253 We engaged agricultural and conservation stakeholders through a survey and workshops to determine

254 evention programmes has failed and called on stakeholders to "get serious about HIV prevention".

255 providers, utilities, regulators, and other stakeholders to accelerate the adoption of innovative te

256 culosis by 2035, we call on all tuberculosis stakeholders to act to accurately diagnose and treat tub

257 2015 agenda represents opportunities for all stakeholders to act together to end all preventable deat

258 sensus conference was convened including key stakeholders to address genetic counseling and testing,

259 following article was developed by multiple stakeholders to address this need.

260 investment in collaboration between diverse stakeholders to create shared value is also important.

261 This knowledge was used by stakeholders to design and implement several actions to

262 sessors, peer reviewers and other interested stakeholders to determine if an assessment meets the cri

263 The importance factors allow stakeholders to determine which factors influence their

264 ium gathered a diverse group of more than 50 stakeholders to develop consensus on a core set of data

265 omen's Health, in October 2014, convened key stakeholders to discuss methods and techniques for integ

266 This will require combined work by all stakeholders to ensure everyone understands the approach

267 Joint efforts by all stakeholders to further promote RG usage in dentistry ar

268 Finally, we urge multiple stakeholders to help mitigate the development of BOS in

269 Finally, we urge multiple stakeholders to help mitigate the development of BOS in

270 for various government, industry, and public stakeholders to improve metal sustainability are discuss

271 disease, realign incentives for all clinical stakeholders to increase kidney transplantation rates, a

272 together multiple disciplines, sectors, and stakeholders to jointly produce the knowledge needed to

273 sional medical societies can work with other stakeholders to lead this effort.

274 must collaborate with administrators and key stakeholders to position themselves to improve economic,

275 human lung fibrosis, engage current and new stakeholders to provide sustained funding for the initia

276 potential reactions by the public and other stakeholders to reproductive modification in forest plan

277 We call on all stakeholders to work together in securing a healthy, pro

278 activities and organizing them according to stakeholder type.

279 to regulatory approval, a workshop with key stakeholders was held in September 2016 to develop a con

280 structure for interweaving science with its stakeholders, we are better able to leverage resources,

281 ops and to inform the debates among relevant stakeholders, we conducted spatiotemporal analyses of Ch

282 As stakeholders, we need to coalesce behind core strategic

283 ts of social-ecological system structure and stakeholders' well-being.

284 , employment, and well-being of marginalized stakeholders were differentially influenced by managemen

285 Main themes identified by stakeholders were that the CPG must be based on best evi

286 arios developed in consultation with country stakeholders, which scaled up existing interventions to

287 information and streamlined discussion among stakeholders while facilitating vaccine distribution dec

288 n strategy ensured the active cooperation of stakeholders while providing an organized and defined fo

289 domains of cost items and by three potential stakeholders who bear the costs.

290 adjustment is of great interest to hospital stakeholders who face substantial financial penalties fr

291 ual in-depth interviews with a wide range of stakeholders who had diverse background and intimate kno

292 e hope that resuscitation councils and other stakeholders will be able to translate this body of know

293 Interaction among diverse scientists and stakeholders will be required to measure the direct and

294 ed here can provide clinicians and other key stakeholders with concrete insights, tools, and strategi

295 borates with other chemical biology database stakeholders with data exchange.

296 ning allergic reactions to food by different stakeholders, with particular reference to the inclusion

297 p, with input from regulatory bodies and key stakeholders, with the goal of developing an algorithmic

298 cal priority, coordinated with international stakeholders within a global approach to reduce the burd

299 opment would be required and a wide range of stakeholders would need to be engaged.

300 comprehensive list of topics that a range of stakeholders would perceive as valid, important, and rel